This trial is active, not recruiting.

Condition advanced adult hepatocellular carcinoma
Treatment conventional transarterial chemoembolization (ctace)
Phase phase 3
Sponsor National Cancer Center, Korea
Start date February 2013
End date July 2017
Trial size 338 participants
Trial identifier NCT01829035, STAH Korea Trial


This is a randomized, multi-center, open-labeled, phase III study in patients with advanced HCC. A total of 338 patients will be randomized (1:1) into one of the two treatment arms, to receive sorafenib with (Arm Combination-treatment; Arm C) or without (Arm Sorafenib alone treatment; Arm S) cTACE.

All the patients will be initially given sorafenib within 72 hours after the randomization. Treatment should continue until the criteria for treatment discontinuation are met.

After the treatment period, patients will undergo follow up for survival every 12 weeks (±7 days) from the last dose, and the survival follow up will be performed for at least 1.5 years after the last patient's last treatment.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
(No Intervention)
sorafenib 400mg bid daily po until progression
after the first Conventional Transarterial Chemoembolization is completed, sorafenib po and cTACE on demand until progression
conventional transarterial chemoembolization (ctace)
Concurrent use of the following material/drug is defined as cTACE in this trial. Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil Anti-tumor drug: Unapproved drug/embolization material from each regulatory agency should not be used. To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed

Primary Outcomes

The overall survival (OS) of oral sorafenib given as monotherapy daily compared to sorafenib with combination cTACE in subjects
time frame: 3.5 years

Secondary Outcomes

Time to progression (TTP)in patients
time frame: 3.5 years
Tumor response rate (TRR)in patients
time frame: 3.5 years
Progression free survival(PFS)will be evaluated
time frame: 3.5 years
Evaluation of adverse events
time frame: 3.5 years

Eligibility Criteria

Male or female participants at least 20 years old.

Inclusion Criteria: To be eligible to participate in the study, patients must meet the following criteria: 1. Signed written informed consent 2. Clinical or histological diagnosis of HCC based on the guidelines of the Korean Liver Cancer Study Group and the National Cancer Center Korea 3. At least one typical enhanced index lesion in the liver that is bi-dimensionally measurable by multiphasic spiral CT scan or dynamic contrast-enhanced MRI, and size of largest tumor is 15 cm or less at enrollment. 4. Tumor conditions confirmed by abdominal imaging (contrast enhanced CT ± MRI) and chest imaging (CT) performed within 4 weeks prior to the treatment initiation: 5. Age of at least 20 years. 6. ECOG Performance Status of 0, 1 or 2. 7. Child-Pugh class A or B (Child-Pugh score ≤ 7). 8. Life expectancy of at least 16 weeks. 9. Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements (no transfusion, no restoration), conducted within 14 days prior to screening: 10. Female patients at least 1 year postmenopausal, surgically sterile or those of childbearing potential must have a negative urine pregnancy test within 14 days prior to the first treatment, and have to use at least one medically acceptable and effective contraceptive method for the last 2 months prior to Screening Visit: methods of effective contraception result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as a barrier method (implant, injectable contraceptives, oral contraceptives, intrauterine contraceptive device), hormonal IUD, sexual abstinence or vasectomized partner. Exclusion Criteria:

Additional Information

Official title A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)
Principal investigator Joong-Won Parkr, Ph.D.
Description The superiority of the Arm C (cTACE+Sorafenib) over the Arm S (Sorafenib) in the OS period will be verified in the ITT set and FAS using a stratified log-rank test. Stratification factors consist of mUICC stage (III vs. IV), Vascular invasion (none and Vp1-2 vs. Vp3-4 and any other presence), Child-Pugh score (5 vs. 6-7), serum AFP level (≥200 ng/mL vs. <200 ng/mL). The significance level is 5% (one-sided).
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by National Cancer Center, Korea.